A poster presentation at the 2023 International Conference on Alzheimers and Parkinsons Diseases and Related Neurological Disorders (AD/PD) highlighted positive results from one such trial, the Phase II ELAD study, which assessed Novo Nordisks liraglutide in mild to moderate Alzheimers
Given an established role of GLP-1 receptor agonists (GLP-1 RAs) in reducing body weight in people who are overweight or obese, with or without diabetes [13,14,15,16,17], it is therefore reasonable to question whether any weight-reducing effects of GLP-1 RAs are mediated trough the modulation of gustatory coding
It is easy to carry and simple to use anytime, making it practical for daily routines
Retatrutide Pharmacokinetics Explained The calculator uses established pharmacokinetic principles to model drug accumulation: Key Parameters: Half-life: ~168 hours (7 days) Dosing interval: Weekly (168 hours) Steady state: Reached after ~5 half-lives Accumulation factor: ~2x the single dose With weekly dosing at the same interval as the half-life, Retatrutide levels will accumulate to approximately double the single-dose level at steady state.
